Microbiotica Enters into Microbiome Collaboration with Genentech
Microbiotica, a leading player in microbiome-based therapeutics spun out of the Wellcome Sanger Institute, announced that it has entered into a multi-year strategic collaboration with Genentech, a member of the Roche Group, to discover, develop and commercialise biomarkers, targets and medicines for inflammatory bowel disease (IBD).
Under the terms of the agreement, Microbiotica will utilise its precision metagenomics microbiome platform to analyse patient samples from clinical trials of Genentech’s investigational IBD medicines, in order to identify microbiome biomarker signatures of drug response, novel IBD drug targets and live bacterial therapeutic products. Microbiotica will receive an undisclosed upfront payment and is eligible to receive research, development and commercialisation milestone payments up to $534 million based on achievement of certain predetermined milestones. In addition, Microbiotica is eligible to receive royalties on sales of certain products resulting from the collaboration. Genentech also has an option to license assets that Microbiotica develops as a result of the research collaboration.
Microbiotica was formed 18 months ago with funding from Cambridge Innovation Capital and IP Group to commercialise ground-breaking microbiome science at the Wellcome Trust Sanger Institute, from the laboratory of Dr Trevor Lawley, CSO of Microbiotica.
The Microbiotica platform comprises the world’s leading microbiome Culture Collection and linked Reference Genome Database that enable unprecedented precision of gut bacterial identification at clinical trial scale. The Company is adding to this at a very rapid rate through its industrial culturing and sequencing pipeline, providing the best available representation of clinical trial samples for strain-level identification of bacteria. The complex datasets that arise from such studies are analysed using AI techniques to discern microbiome signatures linked to phenotype. The availability of the physical Culture Collection enables biological evaluation of bacteria in proprietary translational models including humanised microbiome mouse models.
Dr Mike Romanos, CEO of Microbiotica, said: “This collaboration brings together a world-class pipeline of investigational IBD medicines from Genentech with the world-class microbiome capability of Microbiotica. We are excited by the opportunity to work with Genentech scientists in order to bring precision metagenomics into the clinical arena for the first time, enabling us to develop biomarkers and medicines for the benefit of patients.”
“This collaboration reflects Microbiotica’s strategy of utilising its platform for medicines and biomarker discovery while simultaneously expanding platform capabilities. Whilst Genentech will retain rights to proprietary biomarkers, targets and medicines, the collaboration will enable Microbiotica to continue to rapidly expand its already leading Reference Genome Database and Culture Collection, further strengthening its value across all therapeutic areas,” added Dr Romanos.
James Sabry, M.D., Ph.D., Senior Vice President and Global Head of Genentech Partnering, said: “We believe the microbiome represents a new paradigm in biomedicine, both for understanding drug response and as a novel therapeutic modality. We have chosen to collaborate with Microbiotica because of its high-quality science and look forward to working together to potentially bring new medicines to people suffering from IBD.”
Cryo-EM Reveals Interaction Between Major Drug TargetsNews
For the first time, scientists have visualized the interaction between two critical components of the body's vast cellular communication network, a discovery that could lead to more effective medications with fewer side effects for conditions ranging from migraine to cancer.READ MORE
New Ovarian Cancer TargetNews
Researchers have found a prescription drug, Calcitriol, approved by the Food and Drug Administration for the treatment of calcium deficiency and kidney diseases, may increase the likelihood of surviving ovarian cancer. This new study opens a potential avenue for treating ovarian cancer. Since Calcitriol is an FDA-approved drug, no additional research is needed before the drug can advance to human clinical trials for ovarian cancer.READ MORE
Comments | 2 ADD COMMENT
Andy Sebi | Jun 12, 2018
Greetings to every one reading these. Am dr Andy senior traditional doctor in charge of Dr sebi healing products in USA. Well many of you should be familiar with dr sebi principle of living a healthy lifestyle, to dose who don't know; it's simply maintaining an Alkaline phosphatase diet, to boast your immune system ; more of food that contains iron to help keep your body tissues strong. What ever the disease might be, just by using these dr.sebi principles you are sure of getting your self cured. Nature has all the answers. Well after dr.sebi demise few years ago his works still live on, nature still live on. All products to boast your immune system to help get rid of deadly disease like: HIV, Herpes, 1&2 ,cancer, Aids , Als, stroke , diabetes, gonorrhea general stds and chronic disease. We have them all. Place your order or need advice , within and outside USA. Contact: firstname.lastname@example.org . We will be glad to join you in the journey for healing. Dr. Andy Sebi.
Daina Slim | Jun 08, 2018
Do anyone still doubt natural herbs? I''ve seen the great importance of natural herbs and the wonderful work they have done in people''s lives. I wonder why people still spend their hard earn money on injections and drugs each time they are sick. Natural herbs can cure herpes, diabetics, asthma, HIV, hepatitis, etc. I''ve seen it with my own eyes. i was cured of HIV by this herbalist doctor who uses natural herbs to cure different kind of illness. Even Dr. Camala prove to the whole world that natural herbs can cure all diseases/viruses and he cured countless of people using natural herbs. i know is had to believe but am a living testimony. If anyone here is sick, why not give it a try, there is no harm in trying. Contact Dr. Camala on: email@example.com whatsap no: +2349055637784